Author:
Sambyal Vasudha,Kaur Sukhpreet,Manjari Mridu,Uppal Manjit Singh,Singh Neeti Rajan,Sudan Meena,Guleria Kamlesh
Funder
Department of Science and Technology
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Barnoud T., Budina-Kolomets A., Basu S., Leu J. I., Good M., Kung C. P. et al. 2018 Tailoring Chemotherapy for the African-centric S47 variant of TP53. Cancer Res. 78, 5694–5705.
2. Basu S., Barnoud T., Kung C. P., Reiss M. and Murphy M. E. 2016 The African-specific S47 polymorphism of p53 alters chemosensitivity. Cell Cycle 15, 2557–2560.
3. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G. et al. 2003 p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387–402.
4. Buyru N., Altinisik J., Demokan S. and Dalay N. 2007 p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect. Prev. 31, 207–213.
5. Cao Z., Song J. H., Park Y. K., Maeng E. J., Nam S. W., Lee J. Y. et al. 2009 The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 56, 114–118.